CagriSema
Overview
CagriSema is a fixed-ratio combination of cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist, both delivered as peptides via subcutaneous injection. Cagrilintide acts on amylin receptors to reduce appetite and slow gastric emptying, while semaglutide enhances insulin secretion and suppresses glucagon.
Mechanism of Action
The combination is intended to achieve greater weight loss than either agent alone in the treatment of obesity..
Research Summary & Key Findings
Phase 2 trials presented in 2023 showed superior weight reduction with CagriSema compared to semaglutide monotherapy in adults with obesity. Adverse events were predominantly gastrointestinal and dose-related. Phase 3 studies are ongoing to evaluate efficacy and safety in larger cohorts and diverse populations.
Clinical Status
CagriSema is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsFind a Provider
Find a verified provider who offers CagriSema therapy in your area.
Browse Provider MapFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply CagriSema.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.